2018
DOI: 10.1016/j.jval.2018.09.104
|View full text |Cite
|
Sign up to set email alerts
|

Pcn22 - Marketing Authorisation Practice of the European Medicines Agency (Ema) in Oncological Indications

Abstract: for BSC were consistent in the validation MAICs for both OS and PFS. CONCLUSIONS: Based on ITCs, evidence suggests nivolumab demonstrates greater overall survival compared to regorafenib, cabozantinib and BSC. Limitations of indirect comparisons without common comparators are acknowledged. As this analysis did not consider comparisons on safety, these findings should be confirmed with real-world evidence evaluating both effectiveness and safety outcomes.

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles